FluoroPharma, Inc. announced today that the United States Patent and Trademark Office issued U.S. Patent No. 7,438,891, cover...
Read More...

FluoroPharma, Inc. announced today that Dr. David Elmaleh, FluoroPharma’s founder and Chief Scientific Advisor, will re...
Read More...

FluoroPharma Inc., a company developing breakthrough molecular imaging agents for the Positron Emission Tomography (PET) mark...
Read More...

FluoroPharma, Inc. announced today that the United States Patent and Trademark Office issued U.S. Patent No. 7,438,891, covering methods of imaging cardiovascular plaque formation using F18 labeled 2-fluorodeoxy-D-glucose (FDG). Thi...
Read Article Here

FluoroPharma Obtains US Patent for Imaging Cardiovascular Plaque using FDG
January 26, 2009

FluoroPharma, Inc. announced today that the United States Patent and Trademark Office issued U.S. Patent No. 7,438,891, covering methods of im... Read Article Here

FluoroPharma, Inc. to Report Preclinical Data on Alzheimer’s Disease and Prostate Cancer PET Imaging Agents
September 8, 2008

FluoroPharma, Inc. announced today that Dr.... Read Article Here

Positive Phase I Safety Results for BFPET
July 23, 2008
Read Article Here

FluoroPharma Expands Technology Platform to Include Agents for Alzheimer’s Disease (AD)
March 26, 2008

Read Article Here

Commencement of Phase I Clinical Trial for BFPET
March 19, 2008

Fl... Read Article Here

Positive Phase I Safety Results for CardioPET
March 3, 2008

Read Article Here

FluoroPharma Expands Board of Directors and Scientific Advisory Board
July 31, 2007

FluoroPharma Inc., a company developing breakthrough cardiovascular PET molecular imaging diagnostics, announced today that Dr. Todd R. Nelson... Read Article Here

Atherosclerotic Plaque Imaging in Proceedings of National Academy of Sciences
October 12, 2006

FluoroPharma announces publication of a major new scientific paper in the Proceedings of National Academy of Sciences demonstrating the abilit... Read Article Here

Peter S. Conti, MD, PhD Joins FluoroPharma’s Board of Directors
October 1, 2006
“We are pleased to have Dr. Conti join our management team,” said David Elmaleh, Chairman and Chief Scientific Advisor of FluoroPharm... Read Article Here

CardioPET Clinical Trials
September 22, 2006

FluoroPharma Inc. announced commencement of Phase I clinical trials for CardioPET, following institutional review board (IRB) approval of the ... Read Article Here

Bench-to-Bedside: New SNM Initiative
June 6, 2006
FluoroPharma is proud to support the most recent initiative of the Society of Nuclear Medicine (SNM) to improve health care outcome by promoting ... Read Article Here